Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Interest Expenses (2016 - 2025)

Enanta Pharmaceuticals filings provide 9 years of Interest Expenses readings, the most recent being $3.1 million for Q4 2025.

  • On a quarterly basis, Interest Expenses rose 57.14% to $3.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.8 million, a 6.97% decrease, with the full-year FY2025 number at $7.7 million, down 29.79% from a year prior.
  • Interest Expenses hit $3.1 million in Q4 2025 for Enanta Pharmaceuticals, up from $2.4 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $3.4 million in Q4 2023 to a low of $1.6 million in Q2 2025.
  • Median Interest Expenses over the past 3 years was $2.4 million (2025), compared with a mean of $2.4 million.
  • Biggest five-year swings in Interest Expenses: plummeted 42.98% in 2024 and later soared 57.14% in 2025.
  • Enanta Pharmaceuticals' Interest Expenses stood at $3.4 million in 2023, then plummeted by 42.98% to $2.0 million in 2024, then surged by 57.14% to $3.1 million in 2025.
  • The last three reported values for Interest Expenses were $3.1 million (Q4 2025), $2.4 million (Q3 2025), and $1.6 million (Q2 2025) per Business Quant data.